Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From <i>EGFR</i> and <i>ALK</i> Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Abstract

The addition of up-front SRS to CNS-penetrant TKI improved time-to-CNS progression and local CNS control, but not OS, in patients with BM from EGFR<i>-</i> and ALK-driven NSCLC. Patients with larger BM (≥1 cm) may benefit the most from up-front SRS.